Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 500 mg

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 12.5 mg - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)] . risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiologic

United States - English - NLM (National Library of Medicine)

cvs pharmacy - avobenzone 3.0%, homosalate 10.0%, octisalate 5.0%, octocrylene 4.0%, oxybenzone 5.0% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see ​directions ​), decreases the risk of skin cancer and early skin aging caused by the sun ​do not use - ​​on damaged or broken skin ​stop use and ask doctor if ​ - rash occurs.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 250 mg - carefully consider the potential benefits and risks of naproxen tablets and other treatment options before deciding to use naproxen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naproxen tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritits naproxen tablets are also indicated: - for relief of the signs and symptoms of tendonitis - for relief of the signs and symptoms of bursitis - for relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary  dymenorrhea naproxen tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type r

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; brilliant scarlet 4r; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks. (see adverse reactions).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; iron oxide yellow; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000 - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United States - English - NLM (National Library of Medicine)

alaven pharmaceutical llc - oxymetholone (unii: l76t0zca8k) (oxymetholone - unii:l76t0zca8k) - oxymetholone 50 mg - anadrol® -50 tablets is indicated in the treatment of anemias caused by deficient red cell production. acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. anadrol® -50 tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin b12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids. controlled substance: anadrol®-50 tablets is considered to be a controlled substance and is listed in schedule iii.

United States - English - NLM (National Library of Medicine)

novitium pharma llc - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - oxybutynin chloride tablets, usp are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). oxybutynin chloride tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. oxybutynin chloride tablets are  also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; saccharin sodium; purified talc; magnesium stearate; mannitol; flavour - seaze is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy therapy in newly diagnosed paediatric patients is not recommended.( see pharmacology, clinical trials.)